Methadone to treat chemotherapy-induced peripheral neuropathy (METACIN): study protocol.
Mathieos Belayneh, Samar Hejazi, Bruno Gagnon...
https://pubmed.ncbi.nlm.nih.gov/40289780/Actively Recruiting
Led by University of British Columbia · Updated on 2025-03-27
50
Participants Needed
4
Research Sites
N/A
Total Duration
Chemotherapy-induced peripheral neuropathy CIPN causes chronic nerve pain affecting up to 70% of cancer patients after chemotherapy. This pain impacts quality of life and daily functioning. Duloxetine is currently the only recommended medication to reduce CIPN pain, but its effect is modest. Methadone, an opioid with unique properties, may offer better pain control and less tolerance over time, but it has not yet been studied for CIPN treatment. This trial compares methadone and duloxetine for treating painful CIPN. Participants will be randomly assigned to receive either methadone or duloxetine for 5 weeks. Both drugs are given in capsules that look identical to maintain blinding. Weekly visits, either in person or virtual, will assess pain and side effects, and dosages will be adjusted as needed to control pain or until the 5-week period ends. During the study, participants will complete questionnaires about their pain and how it affects their function and quality of life. Researchers will monitor side effects and adjust doses weekly. The main measure is the change in average pain intensity over 5 weeks using a standard pain inventory. Other outcomes include effects on daily function, quality of life, and medication tolerance. Participants are followed closely throughout the treatment period, which lasts about 5 weeks.
CONDITIONS
Methadone to Treat Painful Chemotherapy Induced Peripheral Neuropathy
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of British Columbia
Lead Sponsor
British Columbia Cancer Agency
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 5 weeks
Participants receive either methadone or duloxetine as treatment for painful chemotherapy-induced peripheral neuropathy. They undergo dose titration based on weekly assessments of pain, adverse events, and tolerability.
Weekly visits (televisit or in-person) for 15 minutes each
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Mathieos Belayneh, Samar Hejazi, Bruno Gagnon...
https://pubmed.ncbi.nlm.nih.gov/40289780/University of British Columbia
Lead Sponsor
British Columbia Cancer Agency
Collaborating Sponsor